Warner-Lambert/RPR sparfloxacin agreement
Executive Summary
Warner-Lambert and Rhone-Poulenc Rorer will co-promote the oral quinolone antibiotic in the U.S. and Canada under a development agreement announced April 1. Warner-Lambert licensed sparfloxacin from Japan's Dainippon in 1989. Rhone-Poulenc Rorer will conduct clinical studies of the product, which is expected soon to enter Phase III for community acquired infections and is already in Phase III for skin infections, pneumonia, bronchitis and complicated urinary tract infections. RPR already has an agreement with Dainippon to develop and market sparfloxacin in Europe. Warner-Lambert will continue its Phase I studies of sparfloxacin for Mycobacterium avium complex in AIDS patients, an indication not included in the co-development deal ("The Pink Sheet" March 23, T&G-5).